Catalent has announced another round of layoffs at its Baltimore facilities, marking its second workforce reduction in Maryland since August. This decision follows a significant decline in demand from a major customer, which previously led to the loss of about 350 jobs. The ongoing layoffs reflect broader challenges in the biotech sector, where over 1,200 jobs have been cut in Maryland alone this year, amid a national trend of more than 32,000 biopharma job losses. The gene therapy manufacturing sector, once a rapidly growing area, is experiencing lower utilization rates and delayed projects, creating a particularly difficult employment environment for specialized professionals. Workforce groups are beginning to implement retraining initiatives to assist displaced workers as the job market becomes increasingly competitive.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://biobuzz.io/news/breaking-catalent-confirms-additional-layoffs-in-maryland-as-gene-therapy-market-headwinds-persist/
